Baxter International (NYSE:BAX) Releases Earnings Results, Beats Estimates By $0.06 EPS

Baxter International (NYSE:BAX) posted its quarterly earnings data on Thursday. The medical instruments supplier reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.52 by $0.06, Zacks reports. The business had revenue of $2.75 billion during the quarter, compared to the consensus estimate of $2.67 billion. Baxter International had a return on equity of 18.30% and a net margin of 0.77%. Baxter International updated its FY 2025 guidance to 2.450-2.550 EPS and its Q1 2025 guidance to 0.470-0.500 EPS.

Baxter International Stock Performance

BAX opened at $33.87 on Friday. Baxter International has a 12-month low of $28.33 and a 12-month high of $44.01. The stock has a market cap of $17.29 billion, a price-to-earnings ratio of 169.33, a PEG ratio of 9.83 and a beta of 0.61. The business has a 50 day moving average of $30.65 and a 200-day moving average of $34.14. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31.

Baxter International Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Friday, February 28th will be given a $0.17 dividend. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.01%. Baxter International’s payout ratio is 340.02%.

Analysts Set New Price Targets

BAX has been the subject of a number of research reports. StockNews.com downgraded Baxter International from a “buy” rating to a “hold” rating in a report on Monday, November 11th. Stifel Nicolaus decreased their price objective on Baxter International from $46.00 to $38.00 and set a “buy” rating for the company in a report on Monday, November 11th. Citigroup decreased their price target on Baxter International from $37.00 to $35.00 and set a “neutral” rating for the company in a research note on Wednesday, December 11th. JPMorgan Chase & Co. decreased their price target on Baxter International from $38.00 to $36.00 and set a “neutral” rating for the company in a research note on Friday. Finally, Barclays began coverage on Baxter International in a research note on Thursday. They issued an “overweight” rating and a $39.00 price target for the company. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Baxter International has an average rating of “Hold” and an average price target of $38.80.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.